Pharmaceutical

FDA expands GSK’s Jemperli approval for endometrial cancer

GSK announced that Jemperli plus chemotherapy has obtained expanded FDA approval for primary advanced or recurrent endometrial cancer.

Aug 3, 2024 - 04:00
FDA expands GSK’s Jemperli approval for endometrial cancer
GSK announced that Jemperli plus chemotherapy has obtained expanded FDA approval for primary advanced or recurrent endometrial cancer.
Read the original article

Tags:

Previous Article

Sanofi invests $1.4bn in insulin production in Germany

Next Article

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bavarian Nordic expands access to mpox vaccine in US

Bavarian Nordic expands access to mpox vaccine in US

Apr 3, 2024

A young girl’s custom gene therapy hints at a framework for tailored rare disease treatments

A young girl’s custom gene therapy hints at a framework...

Jul 12, 2023

STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?

STAT+: What does America’s crackdown on Chinese firms m...

Feb 29, 2024